{"pmid":32392759,"title":"Marine Algal Antioxidants as Potential Vectors for Controlling Viral Diseases.","text":["Marine Algal Antioxidants as Potential Vectors for Controlling Viral Diseases.","As the COVID-19 epidemic expands in the world, and with the previous SARS epidemic, avian flu, Ebola and AIDS serving as a warning, biomedical and biotechnological research has the task to find solutions to counteract viral entry and pathogenesis. A novel approach can come from marine chemodiversity, recognized as a relevant source for developing a future natural \"antiviral pharmacy\". Activities of antioxidants against viruses can be exploited to cope with human viral infection, from single individual infections to protection of populations. There is a potentially rich and fruitful reservoir of such compounds thanks to the plethora of bioactive molecules and families present in marine microorganisms. The aim of this communication is to present the state-of-play of what is known on the antiviral activities recognized in (micro)algae, highlighting the different molecules from various algae and their mechanisms of actions, when known. Given the ability of various algal molecules-mainly sulfated polysaccharides-to inhibit viral infection at Stage I (adsorption and invasion of cells), we envisage a need to further investigate the antiviral ability of algae, and their mechanisms of action. Given the advantages of microalgal production compared to other organisms, the opportunity might become reality in a short period of time.","Antioxidants (Basel)","Sansone, Clementina","Brunet, Christophe","Noonan, Douglas M","Albini, Adriana","32392759"],"abstract":["As the COVID-19 epidemic expands in the world, and with the previous SARS epidemic, avian flu, Ebola and AIDS serving as a warning, biomedical and biotechnological research has the task to find solutions to counteract viral entry and pathogenesis. A novel approach can come from marine chemodiversity, recognized as a relevant source for developing a future natural \"antiviral pharmacy\". Activities of antioxidants against viruses can be exploited to cope with human viral infection, from single individual infections to protection of populations. There is a potentially rich and fruitful reservoir of such compounds thanks to the plethora of bioactive molecules and families present in marine microorganisms. The aim of this communication is to present the state-of-play of what is known on the antiviral activities recognized in (micro)algae, highlighting the different molecules from various algae and their mechanisms of actions, when known. Given the ability of various algal molecules-mainly sulfated polysaccharides-to inhibit viral infection at Stage I (adsorption and invasion of cells), we envisage a need to further investigate the antiviral ability of algae, and their mechanisms of action. Given the advantages of microalgal production compared to other organisms, the opportunity might become reality in a short period of time."],"journal":"Antioxidants (Basel)","authors":["Sansone, Clementina","Brunet, Christophe","Noonan, Douglas M","Albini, Adriana"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32392759","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/antiox9050392","keywords":["covid-19","algae","antioxidant","antiviral","marine"],"e_drugs":["Polysaccharides"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666627828058161152,"score":9.490897,"similar":[{"pmid":32325124,"pmcid":"PMC7169894","title":"Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals.","text":["Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals.","This article examines three aspects of antivirals, such as hydroxychloroquine, chloroquine, and remdesvir, as they might relate to the treatment of a viral infection such as COVID-19: (i) the use of vaporization for the delivery of antivirals, with the bulk constituents having mild antiviral efficacy; (ii) the application of a marine natural product extract as opposed to a single molecule as an antiviral agent; and (iii) a counter intuitive approach to formulation that is, in part, based on delivering multiple species that fall into three categories: building blocks for the virus to accelerate replication; an energy source for the infected cell to boost its immune response; and the species that antagonize or provide toxicity to the virus.","Drug Discov Today","Manning, Thomas J","Thomas-Richardson, Jenu","Cowan, Matthew","Beard, Torien","32325124"],"abstract":["This article examines three aspects of antivirals, such as hydroxychloroquine, chloroquine, and remdesvir, as they might relate to the treatment of a viral infection such as COVID-19: (i) the use of vaporization for the delivery of antivirals, with the bulk constituents having mild antiviral efficacy; (ii) the application of a marine natural product extract as opposed to a single molecule as an antiviral agent; and (iii) a counter intuitive approach to formulation that is, in part, based on delivering multiple species that fall into three categories: building blocks for the virus to accelerate replication; an energy source for the infected cell to boost its immune response; and the species that antagonize or provide toxicity to the virus."],"journal":"Drug Discov Today","authors":["Manning, Thomas J","Thomas-Richardson, Jenu","Cowan, Matthew","Beard, Torien"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32325124","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.drudis.2020.04.010","topics":["Treatment"],"weight":1,"_version_":1666138493922836481,"score":300.19315},{"pmid":32410504,"title":"Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2. A molecular dynamic study.","text":["Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2. A molecular dynamic study.","Sever acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a single-stranded RNA (ssRNA) virus, responsible for severe acute respiratory disease (COVID-19). A large number of natural compounds are under trial for screening compounds, possessing potential inhibitory effect against the viral infection. Keeping in view the importance of marine compounds in antiviral activity, we investigated the potency of some marine natural products to target SARS-CoV-2 main protease (M(pro)) (PDB ID 6MO3). The crystallographic structure of M(pro) in an apo form was retrieved from Protein Data Bank and marine compounds from PubChem. These structures were prepared for docking and the complex with good docking score was subjected to molecular dynamic (MD) simulations for a period of 100ns. To measure the stability, flexibility, and average distance between the target and compounds, root means square deviations (RMSD), root means square fluctuation (RMSF), and the distance matrix were calculated. Among five marine compounds, C-1 (PubChem CID 11170714) exhibited good activity, interacting with the active site and surrounding residues, forming many hydrogen and hydrophobic interactions. The C-1 also attained a stable dynamic behavior, and the average distance between compound and target remains constant. In conclusion, marine natural compounds may be used as a potential inhibitor against SARS-CoV-2 for better management of COVID-19.","J Biomol Struct Dyn","Khan, Muhammad Tahir","Ali, Arif","Wang, Qiankun","Irfan, Muhammad","Khan, Abbas","Zeb, Muhammad Tariq","Zhang, Yu-Juan","Chinnasamy, Sathishkumar","Wei, Dong-Qing","32410504"],"abstract":["Sever acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a single-stranded RNA (ssRNA) virus, responsible for severe acute respiratory disease (COVID-19). A large number of natural compounds are under trial for screening compounds, possessing potential inhibitory effect against the viral infection. Keeping in view the importance of marine compounds in antiviral activity, we investigated the potency of some marine natural products to target SARS-CoV-2 main protease (M(pro)) (PDB ID 6MO3). The crystallographic structure of M(pro) in an apo form was retrieved from Protein Data Bank and marine compounds from PubChem. These structures were prepared for docking and the complex with good docking score was subjected to molecular dynamic (MD) simulations for a period of 100ns. To measure the stability, flexibility, and average distance between the target and compounds, root means square deviations (RMSD), root means square fluctuation (RMSF), and the distance matrix were calculated. Among five marine compounds, C-1 (PubChem CID 11170714) exhibited good activity, interacting with the active site and surrounding residues, forming many hydrogen and hydrophobic interactions. The C-1 also attained a stable dynamic behavior, and the average distance between compound and target remains constant. In conclusion, marine natural compounds may be used as a potential inhibitor against SARS-CoV-2 for better management of COVID-19."],"journal":"J Biomol Struct Dyn","authors":["Khan, Muhammad Tahir","Ali, Arif","Wang, Qiankun","Irfan, Muhammad","Khan, Abbas","Zeb, Muhammad Tariq","Zhang, Yu-Juan","Chinnasamy, Sathishkumar","Wei, Dong-Qing"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32410504","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1080/07391102.2020.1769733","keywords":["covid-19","dock","interactions","marine drugs"],"e_drugs":["Carbon"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666897319071580161,"score":284.83652},{"pmid":32340389,"title":"Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.","text":["Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.","The current emergency due to the worldwide spread of the COVID-19 caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a great concern for global public health. Already in the past, the outbreak of severe acute respiratory syndrome (SARS) in 2003 and Middle Eastern respiratory syndrome (MERS) in 2012 demonstrates the potential of coronaviruses to cross-species borders and further underlines the importance of identifying new-targeted drugs. An ideal antiviral agent should target essential proteins involved in the lifecycle of SARS-CoV. Currently, some HIV protease inhibitors (i.e., Lopinavir) are proposed for the treatment of COVID-19, although their effectiveness has not yet been assessed. The main protease (M(pr)) provides a highly validated pharmacological target for the discovery and design of inhibitors. We identified potent M(pr) inhibitors employing computational techniques that entail the screening of a Marine Natural Product (MNP) library. MNP library was screened by a hyphenated pharmacophore model, and molecular docking approaches. Molecular dynamics and re-docking further confirmed the results obtained by structure-based techniques and allowed this study to highlight some crucial aspects. Seventeen potential SARS-CoV-2 M(pr) inhibitors have been identified among the natural substances of marine origin. As these compounds were extensively validated by a consensus approach and by molecular dynamics, the likelihood that at least one of these compounds could be bioactive is excellent.","Mar Drugs","Gentile, Davide","Patamia, Vincenzo","Scala, Angela","Sciortino, Maria Teresa","Piperno, Anna","Rescifina, Antonio","32340389"],"abstract":["The current emergency due to the worldwide spread of the COVID-19 caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a great concern for global public health. Already in the past, the outbreak of severe acute respiratory syndrome (SARS) in 2003 and Middle Eastern respiratory syndrome (MERS) in 2012 demonstrates the potential of coronaviruses to cross-species borders and further underlines the importance of identifying new-targeted drugs. An ideal antiviral agent should target essential proteins involved in the lifecycle of SARS-CoV. Currently, some HIV protease inhibitors (i.e., Lopinavir) are proposed for the treatment of COVID-19, although their effectiveness has not yet been assessed. The main protease (M(pr)) provides a highly validated pharmacological target for the discovery and design of inhibitors. We identified potent M(pr) inhibitors employing computational techniques that entail the screening of a Marine Natural Product (MNP) library. MNP library was screened by a hyphenated pharmacophore model, and molecular docking approaches. Molecular dynamics and re-docking further confirmed the results obtained by structure-based techniques and allowed this study to highlight some crucial aspects. Seventeen potential SARS-CoV-2 M(pr) inhibitors have been identified among the natural substances of marine origin. As these compounds were extensively validated by a consensus approach and by molecular dynamics, the likelihood that at least one of these compounds could be bioactive is excellent."],"journal":"Mar Drugs","authors":["Gentile, Davide","Patamia, Vincenzo","Scala, Angela","Sciortino, Maria Teresa","Piperno, Anna","Rescifina, Antonio"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32340389","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.3390/md18040225","keywords":["covid-19","sars-cov-2","docking","marine natural product","virtual screening"],"e_drugs":["Lopinavir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495859556355,"score":243.06096},{"pmid":32457038,"title":"Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.","text":["Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.","The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the death of more than 328,000 persons worldwide in the first 5 months of 2020. Herculean efforts to rapidly design and produce vaccines and other antiviral interventions are ongoing. However, newly evolving viral mutations, the prospect of only temporary immunity, and a long path to regulatory approval pose significant challenges and call for a common, readily available and inexpensive treatment. Strategic drug repurposing combined with rapid testing of established molecular targets could provide a pause in disease progression. SARS-CoV-2 shares extensive structural and functional conservation with SARS-CoV-1 including engagement of the same host cell receptor (ACE2) localized in cholesterol-rich microdomains. These lipid-enveloped viruses encounter the endosomal/lysosomal host compartment in a critical step of infection and maturation. Niemann-Pick type C (NP-C) disease is a rare, monogenic neurodegenerative disease caused by deficient efflux of lipids from the late endosome/lysosome (LE/L). The NP-C disease-causing gene (NPC1) has been strongly associated with viral infection, as a filovirus receptor (e.g., Ebola) and through LE/L lipid trafficking. This suggests NPC1 inhibitors or NP-C disease mimetics could serve as anti-SARS-CoV-2 agents. Fortunately, there are such clinically approved molecules that elicit antiviral activity in pre-clinical studies, without causing NP-C disease. Inhibition of NPC1 may impair viral SARS-CoV-2 infectivity via several lipid-dependent mechanisms, which disturb the microenvironment optimum for viral infectivity. We suggest that known mechanistic information on NPC1 could be utilized to identify existing and future drugs to treat COVID-19.","J Lipid Res","Sturley, Stephen","Rajakumar, Tamayanthi","Hammond, Natalie","Higaki, Katsumi","Marka, Zsuzsa","Marka, Szabolcs","Munkacsi, Andrew","32457038"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the death of more than 328,000 persons worldwide in the first 5 months of 2020. Herculean efforts to rapidly design and produce vaccines and other antiviral interventions are ongoing. However, newly evolving viral mutations, the prospect of only temporary immunity, and a long path to regulatory approval pose significant challenges and call for a common, readily available and inexpensive treatment. Strategic drug repurposing combined with rapid testing of established molecular targets could provide a pause in disease progression. SARS-CoV-2 shares extensive structural and functional conservation with SARS-CoV-1 including engagement of the same host cell receptor (ACE2) localized in cholesterol-rich microdomains. These lipid-enveloped viruses encounter the endosomal/lysosomal host compartment in a critical step of infection and maturation. Niemann-Pick type C (NP-C) disease is a rare, monogenic neurodegenerative disease caused by deficient efflux of lipids from the late endosome/lysosome (LE/L). The NP-C disease-causing gene (NPC1) has been strongly associated with viral infection, as a filovirus receptor (e.g., Ebola) and through LE/L lipid trafficking. This suggests NPC1 inhibitors or NP-C disease mimetics could serve as anti-SARS-CoV-2 agents. Fortunately, there are such clinically approved molecules that elicit antiviral activity in pre-clinical studies, without causing NP-C disease. Inhibition of NPC1 may impair viral SARS-CoV-2 infectivity via several lipid-dependent mechanisms, which disturb the microenvironment optimum for viral infectivity. We suggest that known mechanistic information on NPC1 could be utilized to identify existing and future drugs to treat COVID-19."],"journal":"J Lipid Res","authors":["Sturley, Stephen","Rajakumar, Tamayanthi","Hammond, Natalie","Higaki, Katsumi","Marka, Zsuzsa","Marka, Szabolcs","Munkacsi, Andrew"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32457038","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1194/jlr.R120000851","keywords":["cholesterol","cholesterol/trafficking","dyslipidemias","ldl/metabolism","lipase/lysosomal","niemann-pick disease","sars-cov-2","storage diseases","coronavirus","drug repurposing","lysosomal storage disease","pandemic"],"e_drugs":["Cholesterol","Lipids"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668141322613030913,"score":222.39847},{"pmid":32284379,"title":"Novel ionophores active against La Crosse virus identified through rapid antiviral screening.","text":["Novel ionophores active against La Crosse virus identified through rapid antiviral screening.","Bunyaviruses are significant human pathogens, causing diseases ranging from hemorrhagic fevers to encephalitis. Among these viruses, La Crosse virus (LACV), a member of the California serogroup, circulates in the eastern and midwestern United States. While LACV infection is often asymptomatic, dozens of cases of encephalitis are reported yearly. Unfortunately, no antivirals have been approved to treat LACV infection. Here, we developed a method to rapidly test potential antivirals against LACV infection. From this screen, we identified several potential antiviral molecules, including known antivirals. Additionally, we identified many novel antivirals that exhibited antiviral activity without affecting cellular viability. Valinomycin, a potassium ionophore, was among our top targets. We found that valinomycin exhibited potent anti-LACV activity in multiple cell types in a dose-dependent manner. Valinomycin did not affect particle stability or infectivity, suggesting that it may preclude virus replication by altering cellular potassium ions, a known determinant of LACV entry. We extended these results to other ionophores and found that the antiviral activity of valinomycin extended to other viral families including bunyaviruses (Rift Valley fever virus, Keystone virus), enteroviruses (Coxsackievirus, rhinovirus), flavirivuses (Zika), and coronaviruses (HCoV-229E and MERS-CoV). In all viral infections, we observed significant reductions in virus titer in valinomycin-treated cells. In sum, we demonstrate the importance of potassium ions to virus infection, suggesting a potential therapeutic target to disrupt virus replication.Importance No antivirals are approved for the treatment of bunyavirus infection. The ability to rapidly screen compounds and identify novel antivirals is one means to accelerate drug discovery for viruses with no approved treatments. We used this approach to screen hundreds of compounds against La Crosse virus, an emerging bunyavirus that causes significant disease, including encephalitis. We identified several known and previously unidentified antivirals. We focused on a potassium ionophore, valinomycin, due to its promising in vitro antiviral activity. We demonstrate that valinomycin, as well as a selection of other ionophores, exhibits activity against La Crosse virus as well as several other distantly related bunyaviruses. We finally observe that valinomycin has activity against a wide array of human viral pathogens, suggesting that disrupting potassium ion homeostasis with valinomycin may be a potent host pathway to target to quell virus infection.","Antimicrob Agents Chemother","Sandler, Zachary J","Firpo, Mason R","Omoba, Oreoluwa S","Vu, Michelle N","Menachery, Vineet D","Mounce, Bryan C","32284379"],"abstract":["Bunyaviruses are significant human pathogens, causing diseases ranging from hemorrhagic fevers to encephalitis. Among these viruses, La Crosse virus (LACV), a member of the California serogroup, circulates in the eastern and midwestern United States. While LACV infection is often asymptomatic, dozens of cases of encephalitis are reported yearly. Unfortunately, no antivirals have been approved to treat LACV infection. Here, we developed a method to rapidly test potential antivirals against LACV infection. From this screen, we identified several potential antiviral molecules, including known antivirals. Additionally, we identified many novel antivirals that exhibited antiviral activity without affecting cellular viability. Valinomycin, a potassium ionophore, was among our top targets. We found that valinomycin exhibited potent anti-LACV activity in multiple cell types in a dose-dependent manner. Valinomycin did not affect particle stability or infectivity, suggesting that it may preclude virus replication by altering cellular potassium ions, a known determinant of LACV entry. We extended these results to other ionophores and found that the antiviral activity of valinomycin extended to other viral families including bunyaviruses (Rift Valley fever virus, Keystone virus), enteroviruses (Coxsackievirus, rhinovirus), flavirivuses (Zika), and coronaviruses (HCoV-229E and MERS-CoV). In all viral infections, we observed significant reductions in virus titer in valinomycin-treated cells. In sum, we demonstrate the importance of potassium ions to virus infection, suggesting a potential therapeutic target to disrupt virus replication.Importance No antivirals are approved for the treatment of bunyavirus infection. The ability to rapidly screen compounds and identify novel antivirals is one means to accelerate drug discovery for viruses with no approved treatments. We used this approach to screen hundreds of compounds against La Crosse virus, an emerging bunyavirus that causes significant disease, including encephalitis. We identified several known and previously unidentified antivirals. We focused on a potassium ionophore, valinomycin, due to its promising in vitro antiviral activity. We demonstrate that valinomycin, as well as a selection of other ionophores, exhibits activity against La Crosse virus as well as several other distantly related bunyaviruses. We finally observe that valinomycin has activity against a wide array of human viral pathogens, suggesting that disrupting potassium ion homeostasis with valinomycin may be a potent host pathway to target to quell virus infection."],"journal":"Antimicrob Agents Chemother","authors":["Sandler, Zachary J","Firpo, Mason R","Omoba, Oreoluwa S","Vu, Michelle N","Menachery, Vineet D","Mounce, Bryan C"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32284379","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1128/AAC.00086-20","locations":["California"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Valinomycin","Potassium"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491408351232,"score":220.95674}]}